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Patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT)
typically receive a ﬁnite period of initial therapy before ASCT. It is not clear if patients with suboptimal (less
than a partial) response to initial therapy beneﬁt from additional alternative therapy with intent to maximize
pretransplant response. We identiﬁed 539 patients with MMwho had an ASCT after having achieved less than
a partial response (PR) to ﬁrst-line induction chemotherapy between 1995 and 2010. These patients were
then divided into 2 groups: those who received additional salvage chemotherapy before ASCT (n ¼ 324) and
those who had no additional salvage chemotherapy immediately before ASCT (n ¼ 215). Additional pre-
transplant chemotherapy resulted in deepening responses in 68% (complete response in 8% and PR in 60%).
On multivariate analysis there was no impact of pretransplant salvage chemotherapy on treatment-related
mortality, risk for relapse, progression-free survival, or overall survival. In conclusion, for patients
achieving less than a PR to initial induction therapy, including with novel agent combinations, additional pre-
ASCT salvage chemotherapy improved the depth of response and pre-ASCT disease status but was not
associated with survival beneﬁt.
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High-dose chemotherapy with autologous hematopoietic
stem cell transplantation (ASCT) has been shown to improve
both overall survival (OS) and disease-free survival for
patients with multiple myeloma (MM) [1-3]. Unfortunately,
the optimal time to transplant patients after initial therapy
to control the disease is not known. In randomized
trials, patients were randomized to ASCT or continuing
Table 1
Baseline Demographics and Characteristics at Transplant
Characteristics NO SALVAGE SALVAGE P
Number of patients 215 324
Number of centers 77 85
Baseline Demographics
Median age at transplant,
yr (range)
57 (33-75) 56 (18-74)
18-39 13 (6) 23 (7) .872
40-49 40 (19) 67 (21)
50-59 84 (39) 113 (35)
60-69 70 (33) 107 (33)
70þ 8 (4) 14 (4)
Male 131 (61) 200 (62) .852
KPS at diagnosis 80 177 (82) 282 (87) .293
Immunoglobulin subtype
IgG 115 (53) 175 (54) .289
IgA 32 (15) 66 (20)
Light chain 45 (21) 59 (19)
Others* 17 (8) 15 (5)
Missing 6 (3) 9 (2)
Durie-Salmon stage
Stage I 17 (8) 15 (5) .093
Stage II 47 (22) 61 (19)
Stage III 104 (48) 150 (46)
Missing 47 (22) 98 (30)
International stage
Stage I 49 (23) 73 (23) .375
Stage II 51 (24) 68 (21)
Stage III 25 (12) 55 (17)
Missing 90 (42) 128 (40)
Serum creatinine at
diagnosis >1.5 mg/dL
36 (17) 86 (27) .012
Number of lines of therapy
1 215 (100) 0 (0) d
2 0 (0) 245 (76)
3 0 (0) 65 (20)
4 0 (0) 14 (4)
Sensitivity to second-line
chemotherapy
197 (61)
Sensitivity to third-line
chemotherapy
47 (59)
Sensitivity to fourth-line
chemotherapy
2 (14)
VAD/corticosteroid-based
ﬁrst-line therapy
130 (60) 152 (47) .002
Bort/Thal/Lena in ﬁrst-line therapy 69 (32) 126 (39) .108
Bort/Thal/Lena beyond ﬁrst line 186 (57)
Characteristics at transplant
Disease status before
transplant
CR 0 (0) 25 (8) <.001
PR 0 (0) 196 (60)
MR/NR/SD 185 (86) 88 (27)
PROG/REL 30 (14) 15 (5)
Sensitivity for chemotherapy
(overall)
Sensitive 0 (0) 221 (68) <.001
Resistant 215 (100) 103 (32)
Median time from diagnosis
to ASCT, mo (range)
7 (2-12) 8 (3-12)
<4 mo 76 (35) 57 (18) <.001
4-8 mo 84 (39) 85 (26)
8-12 mo 55 (26) 182 (56)
Number of transplants
Single transplant 149 (69) 219 (68) .660
Planned tandem transplantz 38 (18) 67 (21)
Second salvage transplantx 28 (13) 38 (12)
Time between ﬁrst
and second HCT
<6 mo 38 (58) 67 (64) .726
6-12 mo 6 (9) 8 (8)
12-24 mo 3 (5) 8 (8)
24-36 mo 4 (6) 4 (4)
>36 mo 15 (23) 18 (17)
(Continued)
Table 1
(continued)
Characteristics NO SALVAGE SALVAGE P
Year of transplant
1995-1996 18 (8) 14 (4) <.001
1997-1998 41 (19) 24 (7)
1999-2000 31 (14) 22 (7)
2001-2002 24 (11) 38 (12)
2003-2004 26 (12) 44 (14)
2005-2006 32 (15) 76 (23)
2007-2008 37 (17) 85 (26)
2009-2010 6 (3) 21 (6)
Median follow-up of survivors,
mo (range)
68 (10-180) 61 (9-181)
KPS indicates Karnofsky Performance Score; Bort/Thal/Lena, bortezomib/
thalidomide/lenalidomide; MR, minimal response; NR, no response; SD,
stable disease; PROG, progression.
Follow-up completeness index as of December 31, 2010: at 1 year, 99%; at
3 years, 95%; and at 5 years, 90%.
* Other isotype: line of chemotherapy ¼ 1: IgD (n ¼ 4), IgM (n ¼ 1),
nonsecretory (n ¼ 12); line of chemotherapy > 1: IgD (n ¼ 2), IgM (n ¼ 1),
nonsecretory (n ¼ 12).
z Planned tandem transplant: Planned and completed tandem transplant
within 6 months after ﬁrst transplant without relapse.
x Secondary salvage transplant: Salvage second transplant after relapse
followed by ﬁrst transplant.
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disease progression after a ﬁxed number of cycles of induc-
tion chemotherapy. However, data suggest that patients with
a lower paraprotein nadir pretransplant have better out-
comes [4]. On the other hand, single-center experiences
suggest that even patients with disease progression after
initial chemotherapy beneﬁt from high-dose chemotherapy
and ASCT [5-8]. The optimal depth of disease response before
ASCT remains uncertain, especially in the context of upfront
ASCT for those with a suboptimal response to initial therapy.
It is unknownwhether such patients should be taken to ASCT
immediately or be switched to a salvage regimen to improve
the level of response.
In this study we examined the effect of additional salvage
chemotherapy on the response rates, progression-free sur-
vival (PFS) and OS among patients achieving a suboptimal
response (deﬁned as less than a partial response [PR]) to
initial therapy of newly diagnosed MM.
METHODS
Patients
From a cohort of ASCT recipients for MM between 1995 and 2010 re-
ported to the Center for International Blood and Marrow Transplant
Research (CIBMTR) within 12 months of the diagnosis, we identiﬁed those
with suboptimal response to initial therapy. Suboptimal response to ﬁrst-
line pretransplant therapy was deﬁned as a failure to achieve at least a PR
to ﬁrst-line chemotherapy. Patients who achieved complete response (CR)
or PR or were missing information of response to ﬁrst-line chemotherapy
were excluded.
The study group consisted of patients failing to achieve at least a PR to
initial induction therapy and was analyzed in 2 cohorts: those who received
additional salvage chemotherapy after nonresponse to ﬁrst-line therapy and
then proceeded to ASCT (SALVAGE, n ¼ 324) and those who had no addi-
tional salvage chemotherapy but proceeded to ASCT immediately (NO
SALVAGE, n ¼ 215). A contemporaneous cohort of those with optimal
response to initial therapy consisting of 463 patients with CR and 1626
patients with a PR to ﬁrst-line chemotherapy was included for survival
comparisons with the study cohort.
Statistics
Descriptive statistics, including demographics variables, disease-related
factors, and transplant-related factors, were tabulated. Characteristics of
Figure 1. (A) PFS of patients who achieved suboptimal response (<PR) vs. an
overall response (CR/PR) to ﬁrst-line induction chemotherapy. (B) OS of pa-
tients who achieved suboptimal response (<PR) vs. an overall response (CR/
PR) to ﬁrst-line induction chemotherapy.
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Wilcoxon test for continuous variables and chi-square test for discrete var-
iables. For discrete variables with small group size, the Fisher’s exact test
was used for comparison.
Standard International Myeloma Working Group criteria were used for
classifying disease responses and deﬁning progression of MM or relapse
(REL) [9]. The probability of PFS and OS were calculated by using the Kaplan-
Meier estimator, with the variance estimated by Greenwood’s formula.
Cumulative incidence curves and probabilities for treatment-related mor-
tality (TRM) were calculated by treating REL as a competing risk. Point-wise
comparisons were used to analyze outcomes of different interest groups. All
tests were 2-sided with a signiﬁcance level of .05.
Patients in the SALVAGE cohort were likely to wait longer to receive a
transplant than those who received only 1 line of treatment. To reduce this
potential waiting time bias, a left-truncated version multivariate analysis
was performed, where the study clock started at diagnosis with left-
truncation time (delay entry time). Multivariate analysis of TRM, REL, PFS,
and OS was performed by using Cox proportional hazards regressionmodels
(left truncated to reduce waiting time bias in the SALVAGE group). The
assumption of proportional hazards for each factor in the Cox model was
tested using time-dependent covariates.When the test indicated differential
effects over time (nonproportional hazards), models were constructed to
break the post-transplant time course into 2 periods, using the maximized
partial likelihood method to ﬁnd the most appropriate breakpoint. The
proportionality assumptions were further tested.Table 2
Best Response after Autologous Transplant
Best response post-ASCT Pretransplant Disease Status*
SALVAGE (n ¼ 324)
Overall n (%) CR PR MR/NR/S
CR 60 (19) 17 35 7
PR 128 (40) 2 92 30
MR/NR/SD 66 (20) 0 32 30
PROG/REL 50 (15) 5 25 15
Unknown 20 (6) 1 12 6
* Censored at second transplant if number of transplants 2.A backward stepwise model selection approach was used to identify all
signiﬁcant risk factors. Each step of model building contained the main ef-
fect: salvage chemotherapy after ﬁrst line versus not. Factors signiﬁcant at a
5% level were kept in the ﬁnal model. The potential correlation between
outcome measures and all signiﬁcant risk factors was tested. Adjusted
probabilities of TRM, REL, PFS, and OSwere calculated using themultivariate
models. Variables considered inmultivariate analysis were age at transplant,
gender, Karnofsky performance score, immunoglobulin subtype, disease
stage, serum creatinine at diagnosis, disease status before transplant, con-
ditioning regimens, time from diagnosis to transplant, type of transplant
(single/tandem), novel agent use (bortezomib/thalidomide/lenalidomide),
and year of transplant.
RESULTS
Patient Characteristics
Among those receiving a ﬁrst ASCT for MM between 1995
and 2010, 539 patients underwent ASCT within 12 months of
diagnosis having failed to achieve a response to initial in-
duction therapy. Of these patients, 215 patients proceeded to
ASCT immediately (NO SALVAGE) and 324 patients received
additional salvage chemotherapy before proceeding to ASCT
(SALVAGE). Most patients received only 1 additional line of
therapy (76%), with 20% receiving 2 additional lines and 4%
receiving more than 2 lines of salvage chemotherapy.
Patients in the SALVAGE and NO SALVAGE cohorts were
well matched for age, gender, performance status, immu-
noglobulin subtype, and disease stage (Table 1). A greater
proportion of patients in the SALVAGE group had a serum
creatinine >1.5 mg/dL at diagnosis (27% versus 17%). A
greater proportion of patients in the NO SALVAGE group (60%
versus 47% in the SALVAGE group) received initial therapy
with corticosteroid-based regimens (high-dose dexametha-
sone or vincristine/adriamycin/dexamethasone [VAD]) in
ﬁrst-line therapy. A greater proportion of patients in the
SALVAGE group had ASCT delayed 8 to 12 months (56%
versus 26%) and had their transplants in the later period of
analysis between 2005 and 2010 (55% versus 35%) (Table 1).
Within the SALVAGE cohort, institution of salvage chemo-
therapy resulted in 8% of patients achieving a CR and 60% a
PR before ASCT. A contemporaneous cohort consisting of
2135 patients (632 patients with CR to ﬁrst-line chemo-
therapy and 1503 patients with a PR) were compared with
the nonresponding cohort (Figure 1).
Comparison with Those with Optimal Response to Initial
Therapy
Median PFS of patients who achieved a CR or PR to ﬁrst-
line chemotherapy was superior compared with those who
achieved a suboptimal (less than a PR) response to ﬁrst-line
chemotherapy (32 versus 23 months, P < .001) (Figure 1A).
Median OS of patients who achieved a CR or PR to ﬁrst-line
chemotherapy was superior to those with suboptimal (less
than a PR) response to ﬁrst-line chemotherapy (79 versus
61 months, P < .001) (Figure 1B).NO SALVAGE (n ¼ 215)
D PROG/REL Overall n (%) MR/NR/SD PROG/REL
1 19 (9) 19 0
4 71 (33) 60 11
4 68 (32) 64 4
5 39 (18) 28 11
1 18 (8) 14 4
Figure 2. TRM, REL/progression, PFS, and OS of SALVAGE vs. NO SALVAGE cohorts.
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Best myeloma responses after ASCT in both cohorts are
summarized in Table 2. As expected, a higher proportion
attained CR in the SALVAGE cohort (19% versus 9% in the NO
SALVAGE group). However, it is likely that the CR rates for the
SALVAGE cohort are an overestimate because centers per-
forming salvage may have been less willing proceed to ASCT
in nonresponders and those patients were not available for
our analysis.Relapse/Progression of MM after ASCT
The 4-year cumulative incidence of REL in the SALVAGE
cohort was 67% (95% conﬁdence interval [CI], 61% to 72%) and
in the NO SALVAGE cohort was 63% (95% CI, 56% to 69%)
(P ¼ .44).PFS and TRM
The 4-year PFS in the SALVAGE group was 30% (95% CI,
24% to 35%) and in the NO SALVAGE group 31% (95% CI, 25% to
38%) (P¼ .72) (Figure 2). The 4-year TRM in the SALVAGE and
NO SALVAGE groups was identical at 4% (95% CI, 2% to 7%)
(P ¼ .46).Figure 3. Effect of salvage on survival in patients with non-response to bor-
tezomib/thalidomide/lenalidomide in ﬁrst-line therapy.Overall Survival
The 4-year OS in the SALVAGE groupwas 66% (95% CI, 60%
to 71%) and in the NO SALVAGE groupwas 59% (95% CI, 51% to
66%) (P¼ .14) (Figure 2). Myeloma progressionwas the major
cause of mortality in both the SALVAGE and NO SALVAGE
groups. There was no difference in OS in the SALVAGE and
NO SALVAGE groups even when the analysis was limited to
the subset of patients who received ﬁrst-line therapy with
novel agents such as bortezomib, thalidomide, and lenali-
domide (Figure 3). Also, there was no difference in OS in the
SALVAGE and NO SALVAGE groups in patients who received
bortezomib and/or lenalidomide therapy (Figure 4). Median
OS of patients was 68 months (95% CI, 59 to 90) for those
patients who attained CR/PR after salvage chemotherapy.
This was superior to the 48-month OS (95% CI, 37 to 60)
observed in the group that had no response to salvage
chemotherapy (P ¼ .009). However, the median OS for those
patients who attained CR/PR after salvage chemotherapywas
not better than the 62months (95% CI, 50 to 69) in thosewho
received no salvage chemotherapy (Figure 5).
Multivariate Analysis
Onmultivariate analysis (Table 3) there was no difference
in TRM, REL, PFS, and OS between the SALVAGE and NOFigure 4. Effect of salvage on survival in patients receiving bortezomib and/or
lenalidomide in ﬁrst-line therapy.
Figure 5. OS of patients who attained CR/PR after salvage compared with no salvage therapy (A) and compared with no response to salvage (B).
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predictive of greater TRM (P ¼ .008) and of shorter OS
(P ¼ .001). We performed additional parallel multivariate
analyses for patients receiving transplant within 18 months
of diagnosis and within 24 months of diagnosis. These
multivariate analyses gave similar results for TRM, REL, PFS,
and OS.
DISCUSSION
Despite the fact that consolidative ASCT has been adopted
as a standard of care for treatment of ﬁt patients withMM for
nearly 2 decades, the appropriate time and duration of pre-
transplant therapy for up-front ASCT continues to be
debated. There is great heterogeneity in clinical practice,
with some centers moving patients to ASCT after a pre-
determined number of cycles of therapy irrespective of depth
of response attained, with a few following through with
ASCT even in the face of disease progression. Others extend
the period of therapy and even consider salvage therapy if a
self-determined “desired” level of response is not attained
and believe that transplant at the time of minimum disease
burden would likely provide the best long-term results. Still
others question the value of ASCT in patients already in CR
after induction therapy, with at least 1 study suggesting no
prolongation in survival for patients in CR after induction
therapy [4].
Before the advent of proteasome inhibitor and immuno-
modulatory drugs, regimens like VAD were frequently used
before transplantation. Very few patients achieved CR after
initial induction therapy, and most CRs occurred post-ASCT
with CR achieved in 25% to 35% of patients after a single
transplant and in 35% to 50% after tandem transplantationTable 3
Multivariate Analysis with Time Clock Starting at Diagnosis
Hazard Ratio
(95% CI)
P
TRM
Main effect: SALVAGE vs. NO SALVAGE .97 (.48-1.94) .9260
Creatinine at diagnosis: 1.5 vs. <1.5 2.7 (1.30-5.71) .0075*
Relapse
Main effect: SALVAGE vs. NO SALVAGE 1.14 (.92-1.42) .2104
Creatinine at diagnosis: 1.5 vs. <1.5 1.01 (.78-1.31) .9168
PFS
Main effect: SALVAGE vs. NO SALVAGE 1.38 (.92-1.38) .2407
Creatinine at diagnosis: 1.5 vs. <1.5 .81 (.88-1.41) .3686
OS
Main effect: SALVAGE vs. NO SALVAGE .90 (.70-1.16) .3965
Creatinine at diagnosis: 1.5 vs. <1.5 1.60 (1.20-2.12) .0011*
* Signiﬁcant.[10]. These trials suggested that the deeper responses, and
especially CR, post-transplant is a surrogate for survival in
this disease [11-16]. However, others challenged the notion
of CR as a surrogate to success and have argued that intrin-
sically aggressive MM, deﬁned by known unfavorable bio-
logical risk factors, overrides the beneﬁt of CR and subgroups
of patients with favorable biological risk factors may achieve
prolonged survival, often without ever achieving CR [10].
The value of depth of response attained pretransplant has
been the subject of analyses by several authors. Modern in-
duction regimens are capable of producing CR in more than
30% of patients before ASCT, and data suggest that CR
attained after induction therapy too may be a surrogate for
survival [17]. Lee at al [18]. examined that importance of
achieving at least a PR before transplant and reported that
patients who had novel agent (ie, bortezomib and/or
thalidomide based) induction had a signiﬁcantly shorter OS
and PFS when at least a PR was not achieved. In contrast, in
patients who did not receive novel agents before ASCT, lack
of at least a PR to induction therapywas not associatedwith a
survival disadvantage. Rosiñol et al. [19] reported that pa-
tients with stable disease after induction therapy have an
outcome comparable with those with chemosensitive
disease.
Several ongoing large, prospective, randomized clinical
trials are seeking to address the issue of the best modern
induction regimen before SCT. These trials will also hopefully
conclusively address the issue of the importance of depth of
response attained pre- and post-ASCT in the era of modern
therapies. However, none of these studies is likely to provide
answers to the questions of optimal response before ASCT
and the role of salvage therapy for those achieving “less than
a desired level” of response. We therefore chose to query the
CIBMTR database in an attempt to address this issue. Our
analysis demonstrated that patients achieving less than a PR
after 1 line of therapy in initial induction have inferior sur-
vival compared with those achieving a PR or CR to initial
therapy. Additional lines of salvage therapy before ASCT
improved the depth of response, with a CR in 8% and PR in
60%. Despite the 68% response rate seen in the SALVAGE
group, this additional salvage therapy before ASCT was not
associated with an improvement in PFS or OS over those
receiving no salvage.
This analysis appears to be of relevance even in the
modern era. Although most patients in this experience
received VAD as initial therapy, 39% of patients did receive
bortezomib and/or an immunomodulatory drug in ﬁrst-line
therapy. Salvage therapy did not seem to improve results of
ASCT evenwhen the analysis was limited to this subgroup of
R. Vij et al. / Biol Blood Marrow Transplant 21 (2015) 335e341340patients treated with novel agents as part of ﬁrst-line in-
duction therapy.
In this study, a greater proportion of patients (82% versus
59%) underwent transplant after 2001 in the SALVAGE versus
NO SALVAGE groups. This probably reﬂects the greater avail-
ability of effective therapies for salvage in this era. Also, a
greater proportion (56% versus 26%) underwent transplant
between 8 and 12 months after diagnosis in the SALVAGE
group. However, a left truncated multivariate analysis was
performed to correct for this bias. A subset analysis looking at
the median OS of patients who attained CR/PR after salvage
chemotherapy was certainly superior to that observed in the
group that had no response to salvage chemotherapy
(P ¼ .009). However, the median OS for those patients who
attained CR/PR after salvage chemotherapy was not better
than those who received no salvage chemotherapy.
The question of whether patients achieving less than a PR
to induction therapy should undergo salvage therapy re-
mains a relevant one. Although modern 3-drug induction
regimens have been reported to produce a PR in >90% of
patients, it is still frequent to encounter patients who have
less than a PRwith these combination therapies. Also, several
patients still receive 2-drug proteasome inhibitor or
immunomodulatory-based regimen where rates of PR are
lower.
Our analysis has its limitations. Because it was neces-
sarily limited to ASCT recipients, we did not capture pa-
tients who received salvage therapy but did not proceed to
transplantation. Although this is a drawback, it is unlikely to
change the conclusion, because such patients who received
salvage but not ASCT presumably have a poorer outcome
(refractory disease or death during salvage therapy) than
the SALVAGE cohort we assembled. Hence, their inclusion
only makes the outcomes among the SALVAGE group worse
than observed in the current study and will not negate our
conclusions. Also, important details on cytogenetics that are
known to affect outcomes of these patients are lacking.
However, it can be argued that nonresponse to induction
therapy in itself is an adverse risk factor, and it is possible
that both cohorts are enriched in patients with adverse
cytogenetics. Despite these limitations, these data indicate
that transplant-eligible patients who achieve a suboptimal
response to initial induction therapy should move on to
planned ASCT rather than receiving additional cycles of
salvage therapy in a quest to deepen the level of response.
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